The Experts below are selected from a list of 2784 Experts worldwide ranked by ideXlab platform

Olli Simell - One of the best experts on this subject based on the ideXlab platform.

  • b and t cell immunity in patients with lysinuric protein intolerance
    Clinical and Experimental Immunology, 1999
    Co-Authors: Mari Lukkarinen, Katriina Parto, Helena Kayhty, R M Olander, Olli Ruuskanen, Olli Vainio, Olli Simell
    Abstract:

    Lysinuric protein intolerance (LPI) is characterized by defective cellular transport of the dibasic amino acids, secondary dysfunction of the urea cycle, aversion to dietary protein, failure to thrive, hepatosplenomegaly and osteoporosis. Because several patients have suffered from recurrent respiratory infections and/or severe generalized varicella, and a few have developed systemic lupus, vasculitis or other autoimmune diseases, we have now evaluated the function of patients' immune systems. Serum concentrations of one to three IgG subclasses were decreased in 10 of the 12 patients studied. Antibody titres against diphtheria, tetanus and Haemophilus influenzae (Hib) were below the detection limit of the assay in four, three and eight of the 11 patients examined, respectively. (Re)vaccination of these 11 patients led to satisfactory responses against tetanus, but two patients still failed to develop measurable antibodies against diphtheria, two against Hib and six against one or more of the three serotypes of 23-valent Pneumococcus Vaccine. The proportions of T cells of all lymphocytes and the proliferative responses of the peripheral blood mononuclear cells were normal. In conclusion, humoral immune responses in some patients with LPI are defective and these patients may benefit from intravenous immunoglobulin therapy.

Zoltan Szekanecz - One of the best experts on this subject based on the ideXlab platform.

  • fri0292 efficacy of a conjugated Pneumococcus Vaccine in rheumatoid arthritis patients treated with etanercept
    Annals of the Rheumatic Diseases, 2014
    Co-Authors: έ Rakόczi, Bianka Perge, E Vegh, Peter Csomor, A Pusztai, Szilvia Szamosi, Nora Bodnar, S Szantό, Gabriella Szucs, Zoltan Szekanecz
    Abstract:

    Background Streptococcus pneumoniae is the most common cause of pneumonia. Prevenar 13, a conjugated Vaccine has been developed and has been widely used int he adult population due to its high immunogenicity. In the general population, its efficacy has been proven at all ages, however, little information has become available regarding the efficacy of Prevenar 13 in biologic-treated rheumatoid arthritis (RA) patients. Objectives Immunogenicity of Prevenar 13 was assessed in a cohort of RA patients treated with etanercept. Methods In this prospective study, 22 RA patients already treated with weekly 50mg sc etanercept in combination with methotrexate (n=15) or in monotherapy (n=7) for at least one year were included (mean age 55.1 years). Altogether 24 osteoarthritis patients not receiving biological therapy served as controls (mean age 63.9 years). Prevenar 13 vaccination was performed in all RA patients (±5 days before/after etanercept treatment) and controls and Pneumococcus antibody levels were assessed at baseline, as well as 4 and 8 weeks after vaccination. Results At baseline, Pneumococcus antibody levels in RA patients and in controls were 110.1±68.2 mg/l and 124.0±99.0 mg/l, respectively. Four weeks after vaccination, antibody levels significantly increased in both groups (RA: 247.7±155.6 mg/l; controls: 417.7±198.3 mg/l vs baseline) (p Conclusions In RA patients treated with etanercept, vaccination with Prevenar 13 is effective, resulting in a two-fold increase in Pneumococcus antibody levels. The efficacy of Prevenar 13 vaccination may be more pronounced in younger patients. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.2652

Mari Lukkarinen - One of the best experts on this subject based on the ideXlab platform.

  • b and t cell immunity in patients with lysinuric protein intolerance
    Clinical and Experimental Immunology, 1999
    Co-Authors: Mari Lukkarinen, Katriina Parto, Helena Kayhty, R M Olander, Olli Ruuskanen, Olli Vainio, Olli Simell
    Abstract:

    Lysinuric protein intolerance (LPI) is characterized by defective cellular transport of the dibasic amino acids, secondary dysfunction of the urea cycle, aversion to dietary protein, failure to thrive, hepatosplenomegaly and osteoporosis. Because several patients have suffered from recurrent respiratory infections and/or severe generalized varicella, and a few have developed systemic lupus, vasculitis or other autoimmune diseases, we have now evaluated the function of patients' immune systems. Serum concentrations of one to three IgG subclasses were decreased in 10 of the 12 patients studied. Antibody titres against diphtheria, tetanus and Haemophilus influenzae (Hib) were below the detection limit of the assay in four, three and eight of the 11 patients examined, respectively. (Re)vaccination of these 11 patients led to satisfactory responses against tetanus, but two patients still failed to develop measurable antibodies against diphtheria, two against Hib and six against one or more of the three serotypes of 23-valent Pneumococcus Vaccine. The proportions of T cells of all lymphocytes and the proliferative responses of the peripheral blood mononuclear cells were normal. In conclusion, humoral immune responses in some patients with LPI are defective and these patients may benefit from intravenous immunoglobulin therapy.

έ Rakόczi - One of the best experts on this subject based on the ideXlab platform.

  • fri0292 efficacy of a conjugated Pneumococcus Vaccine in rheumatoid arthritis patients treated with etanercept
    Annals of the Rheumatic Diseases, 2014
    Co-Authors: έ Rakόczi, Bianka Perge, E Vegh, Peter Csomor, A Pusztai, Szilvia Szamosi, Nora Bodnar, S Szantό, Gabriella Szucs, Zoltan Szekanecz
    Abstract:

    Background Streptococcus pneumoniae is the most common cause of pneumonia. Prevenar 13, a conjugated Vaccine has been developed and has been widely used int he adult population due to its high immunogenicity. In the general population, its efficacy has been proven at all ages, however, little information has become available regarding the efficacy of Prevenar 13 in biologic-treated rheumatoid arthritis (RA) patients. Objectives Immunogenicity of Prevenar 13 was assessed in a cohort of RA patients treated with etanercept. Methods In this prospective study, 22 RA patients already treated with weekly 50mg sc etanercept in combination with methotrexate (n=15) or in monotherapy (n=7) for at least one year were included (mean age 55.1 years). Altogether 24 osteoarthritis patients not receiving biological therapy served as controls (mean age 63.9 years). Prevenar 13 vaccination was performed in all RA patients (±5 days before/after etanercept treatment) and controls and Pneumococcus antibody levels were assessed at baseline, as well as 4 and 8 weeks after vaccination. Results At baseline, Pneumococcus antibody levels in RA patients and in controls were 110.1±68.2 mg/l and 124.0±99.0 mg/l, respectively. Four weeks after vaccination, antibody levels significantly increased in both groups (RA: 247.7±155.6 mg/l; controls: 417.7±198.3 mg/l vs baseline) (p Conclusions In RA patients treated with etanercept, vaccination with Prevenar 13 is effective, resulting in a two-fold increase in Pneumococcus antibody levels. The efficacy of Prevenar 13 vaccination may be more pronounced in younger patients. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.2652

Katriina Parto - One of the best experts on this subject based on the ideXlab platform.

  • b and t cell immunity in patients with lysinuric protein intolerance
    Clinical and Experimental Immunology, 1999
    Co-Authors: Mari Lukkarinen, Katriina Parto, Helena Kayhty, R M Olander, Olli Ruuskanen, Olli Vainio, Olli Simell
    Abstract:

    Lysinuric protein intolerance (LPI) is characterized by defective cellular transport of the dibasic amino acids, secondary dysfunction of the urea cycle, aversion to dietary protein, failure to thrive, hepatosplenomegaly and osteoporosis. Because several patients have suffered from recurrent respiratory infections and/or severe generalized varicella, and a few have developed systemic lupus, vasculitis or other autoimmune diseases, we have now evaluated the function of patients' immune systems. Serum concentrations of one to three IgG subclasses were decreased in 10 of the 12 patients studied. Antibody titres against diphtheria, tetanus and Haemophilus influenzae (Hib) were below the detection limit of the assay in four, three and eight of the 11 patients examined, respectively. (Re)vaccination of these 11 patients led to satisfactory responses against tetanus, but two patients still failed to develop measurable antibodies against diphtheria, two against Hib and six against one or more of the three serotypes of 23-valent Pneumococcus Vaccine. The proportions of T cells of all lymphocytes and the proliferative responses of the peripheral blood mononuclear cells were normal. In conclusion, humoral immune responses in some patients with LPI are defective and these patients may benefit from intravenous immunoglobulin therapy.